Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis-Reference-Cited by-同舟云学术

Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis

Published:2015-12 Issue:7 Volume:149 Page:1775-1783.e2
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Yoshimura Naoki,Watanabe Mamoru,Motoya Satoshi,Tominaga Keiichi,Matsuoka Katsuyoshi,Iwakiri Ryuichi,Watanabe Kenji,Hibi Toshifumi

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference29 articles.

1. Inflammatory bowel disease: cause and immunobiology;Baumgart;Lancet,2007

2. Lymphocyte homing and its role in the pathogenesis of IBD;Eksteen;Inflamm Bowel Dis,2008

3. Differential expression of mucosal addressin cell adhesion molucule-1 (MAdCAM-1) in ulcerative colitis and Crohn’s disease;Arihiro;Pathol Int,2002

4. Therapeutic anti-integrin (α4 and αL) monoclonal antibodies: two-edged swords?;González-Amaro;Immunology,2005

5. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue;Briskin;Am J Pathol,1997

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins;The Korean Journal of Gastroenterology;2024-08-25

2. Consistent efficacy outcomes between phase 2 and phase 3 trials in Crohn’s disease or ulcerative colitis in adults: a meta-analysis;Inflammation Research;2024-04-08

3. Comprehensive overview of novel chemical drugs for ulcerative colitis: focusing on phase 3 and beyond;Expert Opinion on Pharmacotherapy;2024-03-23

4. Effects of rifampicin on the pharmacokinetics and safety of carotegrast methyl in healthy subjects: A randomized 2 × 2 crossover study;British Journal of Clinical Pharmacology;2024-02-26

5. Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials;Expert Opinion on Emerging Drugs;2024-01-02